Teva Pharmaceutical/$TEVA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Teva Pharmaceutical
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
- Ticker
- $TEVA
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 32,008
- Headquarters
- Tel Aviv-Yafo, Israel
- Website
- www.tevapharm.com
TEVA Metrics
BasicAdvanced
$52B
104.25
$0.43
0.84
-
Price and volume
Market cap
$52B
Beta
0.84
52-week high
$44.57
52-week low
$38.11
Average daily volume
7.1M
Financial strength
Current ratio
0.947
Quick ratio
0.514
Long term debt to equity
1.621
Total debt to equity
2.127
Interest coverage (TTM)
4.69%
Profitability
EBITDA (TTM)
4,405
Gross margin (TTM)
52.93%
Net profit margin (TTM)
2.94%
Operating margin (TTM)
19.53%
Effective tax rate (TTM)
-36.66%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
5.35%
Return on equity (TTM)
6.65%
Valuation
Price to earnings (TTM)
104.252
Price to revenue (TTM)
2.992
Price to book
6.51
Price to tangible book (TTM)
-4.69
Price to free cash flow (TTM)
97.454
Free cash flow yield (TTM)
1.03%
Free cash flow per share (TTM)
0.457
Growth
Revenue change (TTM)
2.71%
Earnings per share change (TTM)
-30.83%
3-year revenue growth (CAGR)
4.10%
10-year revenue growth (CAGR)
-1.62%
3-year earnings per share growth (CAGR)
-41.11%
10-year earnings per share growth (CAGR)
-13.00%
What the Analysts think about TEVA
Analyst ratings (Buy, Hold, Sell) for Teva Pharmaceutical stock.
Analyst projections of the future price of Teva Pharmaceutical stock.
Bulls say / Bears say
AUSTEDO, AJOVY and UZEDY generated about $1.1 billion in Q3 revenue, up 33% year on year in local-currency terms. Teva raised its 2026 sales outlook for all three, supporting its shift towards higher-growth innovative medicines. (Teva Pharmaceutical Industries)
Teva expects biosimilar sales to top $800 million in 2026, reaching its 2027 target a year early. Recent FDA approvals and an expanded Samsung Bioepis partnership add products that could support further growth. (Teva Pharmaceutical Industries, Teva Pharmaceuticals)
All three major credit agencies have upgraded Teva to investment grade in recent months. That reflects improved financial standing and should help the company refinance debt on better terms as it continues to reduce borrowings. (Teva Pharmaceutical Industries, Moody’s Ratings)
The generic-drug business remains a drag: global generics revenue fell 16% in Q3, while US generic-product sales dropped 39%, mainly because of stronger competition for lenalidomide. This outweighed growth in Teva’s innovative brands and helped push total revenue down 2%. (Teva Pharmaceutical Industries)
AUSTEDO faces near-term sales volatility as pricing changes and customer buying patterns shift ahead of IRA implementation. Management expected its Q4 2026 revenue to fall year on year, despite raising the full-year outlook for the product. (The Motley Fool)
Teva still carries substantial debt: Moody’s put gross debt-to-EBITDA at about 4.0 times at June 2026, including its adjustment for opioid liabilities. The agency expects leverage to fall, but says the current level remains a constraint on the credit profile. (Moody’s Ratings)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
TEVA Financial Performance
Revenues and expenses
TEVA Earnings Performance
Company profitability
Upcoming events
No upcoming events
TEVA News
AllArticlesVideos
Funds containing TEVA
AllUSDEUR
Fund name | Fund size | $TEVA weighting |
|---|---|---|
SPDR MSCI World Health Care£HEAW | $708M | 0.56% |
SPDR MSCI World Health Care$WHEA | $708M | 0.56% |
Xtrackers MSCI World Health Care$XDWH | $4.1B | 0.54% |
Xtrackers MSCI World Health Care£XWHS | $4.1B | 0.54% |
iShares Edge MSCI World Value Factor€IS3S | $7.1B | 0.26% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.